DURECT Corp (DRRX) Tops Q3 EPS by 1c; Issues Update on DUR-928 Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to DURECT Corp (DRRX) Tops Q3 EPS by 1c; Issues Update on DUR-928 Program
October 31, 2016 4:03 PM EDT
CUPERTINO, Calif., Oct. 31, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2016.  Total revenues were $3.7 million and net loss was $8.8 million for the three months ended September 30, 2016 as compared to total revenues of $4.7 million and net loss of $6.5 million for the three months ended September 30, 2015.  Â
At September 30, 2016, we had cash and investments of $29.0 million, compared to cash and investments of $29.3 million at December 31, 2015. At September 30, 2016, we had $19.8 million in long term debt.
"We are pleased to have provided a separate... More
October 31, 2016 4:02 PM EDT
CUPERTINO, Calif., Oct. 31, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program including a description of data from the first cohort of a Phase 1b study with DUR-928 in patients with nonalcoholic steatohepatitis (NASH).
"We are pleased to report data from cohort one of the first patient study with DUR-928, and that a single dose provided signals of DUR-928 activity in cirrhotic and non-cirrhotic NASH patients," stated James E. Brown, D.V.M., President and CEO of DURECT. "These recent DUR-928 data in patients are... More
